Fatigue, Depressive Disorders and Insomnia in Adult Patients With Marfan Syndrome and Ehlers-Danlos Syndrome: Survey (FAMED)
Observational Survey on Fatigue Levels in Relation to Depressive Disorders and Insomnia in Adult Patients With Marfan Syndrome and Hypermobile Ehlers-Danlos Syndrome
The goal of this observational study is to describe and assess the presence of perceived fatigue in subjects with MFS and EDS. the main question it aims to answer through the FSS instrument is:
- The relationship of fatigue with physical and psychological characteristics, the presence of depressive disorders and insomnia.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Marfan syndrome (MFS) and hypermobile Ehlers-Danlos Syndrome (hEDS) are rare diseases of the connective tissue presenting peculiar symptoms as well as high mortality due to complications related to dilatation and dissection of the ascending aorta and great arteries. Life expectancy of patients with MFS and hEDS has improved markedly in the last decades, but still remains lower than that of the general population. Fatigue represent one of the main causes that limit the quality of life in these populations. The Fatigue Severity Scale (FSS) is a questionnaire widely used in populations with chronic diseases and has been previously applied in MFS and hEDS population: indeed, fatigue interferes with activities of daily living and the presence of chronic pain. However, the potential correlations that fatigue may have with different aspects of psychological well-being (i.e. insomnia and depression) were not investigated in MFS and hEDS.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Lombardy
-
San Donato Milanese, Lombardy, Italy, 20097
- IRCCS Policlinico San Donato
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Enrollment of 200 subjects with MFS and hEDS currently in follow-up at the Cardiovascular Genetic Centre, IRCCS Policlinico San Donato. The study includes the involvement of subjects with hEDS currently in follow-up at Fondazione Ca' Granda IRCCS Policliclinico.
Description
Inclusion Criteria:
- Subjects aged 18 or greater with clinical and/or genetic diagnosis of Marfan syndrome;
- Subjects aged 18 or greater with clinical and/or genetic diagnosis of hypermobile Ehlers-Danlos syndrome;
- Signed informed consent;
- Ability to speak, read and write in Italian.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: CROSS_SECTIONAL
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
MFS_cohort
Adult patients with Marfan syndrome |
Questionnaire for fatigue assessment |
|
hEDS_cohort
Adult patients with hypermobile Ehlers-Danlos syndrome |
Questionnaire for fatigue assessment |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical and psychological features
Time Frame: 10 months
|
The mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions. |
10 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychosocial variables
Time Frame: 10 months
|
The bivariate correlation analysis will be performed by calculating the Pearson or Spearman correlation coefficient |
10 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Mental Disorders
- Pathologic Processes
- Heart Diseases
- Disease Attributes
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Behavioral Symptoms
- Hematologic Diseases
- Sleep Wake Disorders
- Skin Diseases
- Congenital Abnormalities
- Cardiovascular Abnormalities
- Heart Defects, Congenital
- Abnormalities, Multiple
- Sleep Disorders, Intrinsic
- Dyssomnias
- Hemostatic Disorders
- Hemorrhagic Disorders
- Skin Diseases, Genetic
- Skin Abnormalities
- Bone Diseases, Developmental
- Collagen Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Behavior
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Hemic and Lymphatic Diseases
- Depression
- Fatigue
- Rare Diseases
- Sleep Initiation and Maintenance Disorders
- Marfan Syndrome
- Ehlers-Danlos Syndrome
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Surveys and Questionnaires
Other Study ID Numbers
Other Study ID Numbers
- FAMED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.